Category: Intellectual property
-
Baby Box Technology for Sick Newborns Licensed to Start-Up
A start-up company is gaining the rights to a technology that helps the breathing of infants suffering from withdrawal from drugs taken by their mothers, and other disruptive conditions.
-
Pfizer, Biotech Partner on RNA Flu Vaccine
A biotechnology company in Germany and drug maker Pfizer are developing a vaccine to prevent seasonal influenza using messenger RNA that instructs cells on production of proteins.
-
Ultra-Sensitive Nanotech Robot Skin Receives Patent
Inventors of a system of sensors packaged in a thin film received a patent for their work that enables robotic devices to better sense conditions in the nearby environment.
-
Start-Up Developing Regenerative Liver Disease Treatments
A new enterprise founded by scientists, is underway developing treatments for advanced liver disorders that combine new drugs with cell and gene therapies to restore or replace liver functions.
-
Allergan Licensing Crispr for Inherited Eye Disease
Drug maker Allergan is acquiring the rights from Editas Medicine to develop an application of the genome-editing technology Crispr for the inherited eye disease Leber congenital amaurosis type 10.
-
Univ. Spin-Off Developing Myelin Disease Treatments Unveiled
A spin-off enterprise from Case Western Reserve University is developing therapies designed to restore the myelin sheath around nerve cells destroyed in multiple sclerosis and other neurological disorders.
-
Merck, Biopharma Partner on Cell-Free Immune System Therapies
Drug maker Merck is acquiring the rights to therapies for cancer and autoimmune disorders based on a technology for developing synthetic proteins from a process that bypasses live cells.
-
Exosome Technology Acquired for TBI, Stroke Therapies
A company developing therapies for brain injuries and neurodegenerative disorders is acquiring the rights to a process that treats these conditions with pieces of RNA transferred in tiny containers call exosomes.
-
UC-Berkeley Gains U.S. Crispr-Cas9 Patent
University of California received a patent for its genome editing technology known as Crispr, with the most widely used editing enzyme called Cas9.
-
$850M Deal Kicks Off RNA Vaccine Research
Drug maker Sanofi is partnering with biotechnology company Translate Bio to develop vaccines against infectious diseases from messenger RNA, material transcribed from genetic codes in DNA.